Changes in smoking status, mental state and plasma clozapine concentration: retrospective cohort evaluation.

Clozapine relapse smoking

Journal

BJPsych bulletin
ISSN: 2056-4694
Titre abrégé: BJPsych Bull
Pays: England
ID NLM: 101650950

Informations de publication

Date de publication:
Dec 2019
Historique:
pubmed: 9 8 2019
medline: 9 8 2019
entrez: 9 8 2019
Statut: ppublish

Résumé

To investigate the percentage of patients who commenced smoking after transferring out of a non-smoking forensic psychiatric unit, the corresponding clozapine dose adjustments, the effects on plasma clozapine/norclozapine concentrations and observed changes in mental state. We reviewed the notes and plasma clozapine/norclozapine concentrations of 46 patients transferred to medium secure units between July 2008 and December 2013. Thirty-five patients commenced smoking. Their median clozapine dose was increased by 50 mg/d. In the non-smokers, the median clozapine dose remained unchanged. Plasma clozapine/norclozapine concentrations were significantly reduced in smokers despite dosage adjustment. Eighteen patients experienced deterioration in mental state after transfer; almost all these patients were smokers. Approximately three-quarters of patients who were non-smokers by virtue of being in a secure non-smoking environment commenced smoking after transfer. Monitoring of clozapine serum levels and assessment of mental state in the immediate period after a change in smoking status is indicated.

Identifiants

pubmed: 31391141
pii: S2056469419000500
doi: 10.1192/bjb.2019.50
pmc: PMC8058886
doi:

Types de publication

Journal Article

Langues

eng

Pagination

271-274

Références

Hum Psychopharmacol. 2012 May;27(3):277-83
pubmed: 22419536
Ann Pharmacother. 2010 Apr;44(4):727-32
pubmed: 20233914
BMJ. 2014 Feb 13;348:g1151
pubmed: 24524926
Eur Arch Psychiatry Clin Neurosci. 2017 Feb;267(1):63-72
pubmed: 26310877
Psychiatr Serv. 2004 May;55(5):491-3
pubmed: 15128955
J Correct Health Care. 2009 Jul;15(3):190-6
pubmed: 19477804
JAMA Intern Med. 2013 May 13;173(9):789-94
pubmed: 23567902
J Clin Psychopharmacol. 2011 Feb;31(1):124-6
pubmed: 21192157
Hum Psychopharmacol. 2011 Apr;26(3):177-87
pubmed: 21455971
J Clin Psychopharmacol. 2004 Feb;24(1):70-8
pubmed: 14709950
Curr Drug Metab. 2007 May;8(4):307-13
pubmed: 17504220
Prim Care Companion CNS Disord. 2015 Feb 19;17(1):
pubmed: 26137357
Int Clin Psychopharmacol. 2013 Jan;28(1):50-6
pubmed: 23104241
Nurs Stand. 2003 Jan 8-14;17(17):33-7
pubmed: 12593092
Schizophr Res. 1992 Dec;8(2):93-102
pubmed: 1360812
J Pharmacol Exp Ther. 1995 Mar;272(3):984-90
pubmed: 7891353

Auteurs

Inti Qurashi (I)

High Secure Services, Ashworth High Secure Hospital, UK.

Paul Stephenson (P)

High Secure Services, Ashworth High Secure Hospital, UK.

Chitra Nagaraj (C)

Low Secure Servies Hollins Park Hospital, UK.

Simon Chu (S)

Department of Psychology, University of Central Lancashire, UK.

Richard Drake (R)

Division of Psychology and Mental Health, University of Manchester, UK.

Lewis Couchman (L)

Therapeutic Drug Monitoring, Analytical Services International, UK.

Robert Flanagan (R)

Toxicology, King's College Hospital NHS Foundation Trust, UK.

Classifications MeSH